Research programme: recombinant human fibrinogen - Pharming Group NV/ProGenetics

Drug Profile

Research programme: recombinant human fibrinogen - Pharming Group NV/ProGenetics

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProGenetics
  • Developer Pharming Group NV
  • Class
  • Mechanism of Action Fibrinogen receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Blood coagulation disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Coagulation-disorders in North America (Parenteral)
  • 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies
  • 25 Jun 2008 Recombinant fibrinogen sub-licensed to Pharming Group NV in North America, Europe and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top